Drug Profile
Research programme: HIV Vpr-based cancer therapy - Inovio
Alternative Names: VGX-100 - Inovio; VGX-150Latest Information Update: 30 Apr 2012
Price :
$50
*
At a glance
- Originator VGX Pharmaceuticals
- Class
- Mechanism of Action Apoptosis stimulants; NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gastric cancer; Lymphoma; Malignant melanoma
Most Recent Events
- 30 Apr 2012 Discontinued - Preclinical for Gastric cancer in USA (unspecified route)
- 30 Apr 2012 Discontinued - Preclinical for Lymphoma in USA (unspecified route)
- 30 Apr 2012 Discontinued - Preclinical for Malignant melanoma in USA (Intratumoural)